The management of patients with epithelial ovarian cancer with no or minimal residual disease at second-look laparotomy after aggressive surgery and platinum-based chemotherapy has not been definitively established. We report the results of a randomized study comparing three more courses of the same chemotherapy inducing the response (21 patients) with whole-abdomen radiotherapy (20 patients). Thirty-eight patients responded to first-line chemotherapy and three had stabilization of disease. In eight patients tumor debulking was performed at second-look laparotomy. No severe toxic effects were noted in both arms. Bowel obstruction occurred in one patient treated with radiotherapy. At a median follow-up of 22 months, 11 of 20 patients in the radiotherapy arm and 6 of 21 in the chemotherapy arm progressed and 9 and 3 patients died, respectively. Although the number of randomized patients is small we stopped the trial because of the survival and progression-free survival advantage of chemotherapy-treated patients.
|Data di pubblicazione:||1990|
|Titolo:||Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look.|
|Autore/i:||M. Bruzzone;L. Repetto;S. Chiara;E. Campora;P. F. Conte;M. Orsatti;V. Vitale;A. Rubagotti;R. Rosso|
|Codice identificativo ISI:||WOS:A1990EE33000019|
|Codice identificativo Scopus:||2-s2.0-0025009230|
|Citazione:||Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look / M. Bruzzone;L. Repetto;S. Chiara;E. Campora;P. F. Conte;M. Orsatti;V. Vitale;A. Rubagotti;R. Rosso. - In: GYNECOLOGIC ONCOLOGY. - ISSN 0090-8258. - STAMPA. - 38(1990), pp. 392-395.|
|Tipologia||Articolo su rivista|
File in questo prodotto:
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris